MediWound Reports New Clinical Data Demonstrating NexoBrid®’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries Prospective clinical data…
MediWound Reports New Clinical Data Demonstrating NexoBrid®’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries Prospective clinical data…
Proceeds to further advance clinical development of BH-30643, a first-in-class, macrocyclic, CNS-active, mutant-selective OMNI-EGFRTM inhibitor for EGFR-mutant NSCLC, and BH-30236,…
Proceeds to further advance clinical development of BH-30643, a first-in-class, macrocyclic, CNS-active, mutant-selective OMNI-EGFRTM inhibitor for EGFR-mutant NSCLC, and BH-30236,…
EDEN PRAIRIE, Minn., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading…
EDEN PRAIRIE, Minn., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading…
The approval marks the first new treatment option for people living with progressive pulmonary fibrosis (PPF) in more than five…
The approval marks the first new treatment option for people living with progressive pulmonary fibrosis (PPF) in more than five…
From Handshake to Breakthrough: How Rakovina & Variational AI Are Cracking the Code on CNS-Penetrant Cancer TherapiesVANCOUVER, British Columbia, Dec.…
From Handshake to Breakthrough: How Rakovina & Variational AI Are Cracking the Code on CNS-Penetrant Cancer TherapiesVANCOUVER, British Columbia, Dec.…